The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Sustained MRD negativity with daratumumab maintenance in multiple myeloma
Jill Corre, PharmD, PhD, The Cancer University Institute of Toulouse Oncopole (IUCT), Toulouse, France, discusses long-term findings from the CASSIOPEIA study evaluating daratumumab maintenance in transplant-eligible newly diagnosed multiple myeloma. She highlights that one in four patients receiving daratumumab-based induction and maintenance achieved sustained measurable residual disease (MRD) negativity over five years, which was associated with a low risk of relapse. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yesterday I presented the registry CASSIOPEIA, the long-term analysis of CASSIOPEIA with 96% of patients from the original population with 8.5 years median follow-up, the longest reported for quadruplets. And CASSIOPEIA is now a long and old story. The design was done more than 10 years ago. And it showed how daratumumab transformed myeloma outcomes, but it also shows how MRD is a precious tool for the myeloma community...
Yesterday I presented the registry CASSIOPEIA, the long-term analysis of CASSIOPEIA with 96% of patients from the original population with 8.5 years median follow-up, the longest reported for quadruplets. And CASSIOPEIA is now a long and old story. The design was done more than 10 years ago. And it showed how daratumumab transformed myeloma outcomes, but it also shows how MRD is a precious tool for the myeloma community. MRD is important because it can identify deep, but above all, sustained responses to treatment. So in the Cassiopeia trial, we observed that among patients treated with the full DARA arm, the patients who received Dara-VTd plus DARA maintenance, one out of four patients reached a negative MRD status sustained during five years. And this response is associated with an excellent outcome, since when you reach such a response, 42 months after the last MRD assessment, 87% of patients are free of relapse. So it shows you how the depth of the response is very important, but the sustained response is very important. And on the contrary, if you lose your MRD negativity, the risk of progression is doubled. So Cassiopeia is maybe the first trial showing how MRD is important for us and how MRD can identify some patients with an excellent outcome.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
